G42, OceanX, G-Tech and the Indonesian Government to Collaborate to Advance Oceanic Research to Protect the Marine Environment
18.11.2022 20:10:00 EET | Business Wire | Press release
G42, the leading UAE-based AI and cloud computing company and global nonprofit ocean exploration organization OceanX, along with G-Tech Digital Asia (G-Tech), and the Government of the Republic of Indonesia via its Coordinating Ministry for Maritime Affairs and Investment (CMMAI) have announced the signing of a Letter of Intent to establish a collaboration to develop ocean research to help protect the marine environment.
In furtherance of this proposed collaboration, G42 intends to deploy G42 Cloud’s large-scale cloud infrastructure and services, remote sensing drone systems by Bayanat, a public listed company at ADX in which G42 owns a majority stake, and cutting-edge marine genomics applications by G42 Healthcare in the support of OceanX’s social welfare mission and its world-class marine research and media vessel the R/V OceanXplorer, to conduct advanced, in-depth analysis of the coastal and oceanic environments.
The Letter of Intent was signed by Mohammad Firman Hidayat, Acting Deputy Coordinating Minister for Maritime Resources, Peng Xiao, Group CEO of G42, Vincent Pieribone, Vice Chairman of OceanX and Michel Hamilton, CEO of G-Tech.
The collaboration will support the aims of the Indonesian government, led by CMMAI, to improve management of marine resources including biodiversity and conservation of ecosystems, through the use of new technology and methodologies and OceanX’s broader mission to explore the ocean and bring it back to the world through educational media.
The project recognizes the importance of detailed mapping of marine resources through advanced technologies in order to protect and preserve the ocean environment and the livelihoods of the communities that are reliant on it. G42 will support OceanX and CMMAI research with a focus on mapping fisheries and marine resources through data-driven e-DNA, socio-economic, and ecological characters in coastal-marine ecosystems. The proposed collaboration also includes training and knowledge transfer to build human capacity and supporting infrastructure for CMMAI.
In line with the UAE’s mandate to explore and leverage advanced technologies to spearhead the efforts towards environmental preservation, G42 is deploying its extensive portfolio of companies to develop new and better ways in which both public and private organizations can address some of the most pressing climate and environmental challenges.
Peng Xiao, Group CEO of G42 commented: “We are proud to be collaborating with CMMAI and OceanX on this project to develop a greater understanding of Indonesia’s marine environment. Better data is vital to developing a more holistic view of our oceans’ condition, and through our work with OceanX, we are looking to support the development of new, tailored solutions and technologies that will help local authorities to protect the marine environment, for the benefit of present and future generations.”
Dr. Prashanth Marpu, Director of Geospatial Centre Of Excellence and Climate Action Program at Bayanat said: “Oceans are highly complex environments, and monitoring and research can present many challenges to researchers and scientists working in this field. Bayanat is applying its expertise in real-time geospatial services and solutions and handling large-scale data to develop the tools that will allow the research community to leverage big data analysis of the maritime environment.”
About G42
G42 is a global leader in creating visionary artificial intelligence for a better tomorrow. Born in Abu Dhabi and operating across the world, G42 champions AI as a powerful force for good. Its people are constantly reimagining what technology can do, applying advanced thinking and innovation to accelerate progress and tackle society’s most pressing problems.
G42 is driving change in the region and beyond, joining forces with nations, corporations and individuals to create the infrastructure for tomorrow’s world. From molecular medicine to space travel and everything in between, G42 realizes exponential possibilities, today.
For further information visit www.g42.ai.
About OceanX
Oceanographic Research & Exploration Foundation (OceanX) is a mission to support scientists to explore the ocean and to bring it back to the world through captivating media. Uniting leading media, science, and philanthropy partners, OceanX utilizes next-gen technology, fearless science, compelling storytelling, and immersive experiences to educate, inspire, and connect the world with the ocean and build a global community deeply engaged with understanding, enjoying, and protecting our oceans. OceanX is an initiative of Dalio Philanthropies, which furthers the diverse philanthropic interests of Dalio family members.
For more information visit www.oceanx.org and follow OceanX on Facebook, Instagram, Twitter, TikTok and LinkedIn.
About Bayanat
Bayanat, an ADX listed public company with majority shareholding by G42, provides comprehensive world-class AI-powered geospatial solutions to a growing number of sectors such as Defense, Environment, Energy & Resources, Smart Cities and Transportation. It’s offering includes topographic, hydrographic and aeronautical products and charts, as well as spatial data surveying, analysis, management, modelling, visualization and cartography services. Bayanat’s solutions harness vast amounts of premium and unique data from a range of sources including Satellites, High Altitude Pseudo Satellites (HAPS) and Earth Observation powered by AI to drive geospatial intelligence (gIQ).
For more information, please visit: www.bayanat.ai
Twitter:
https://twitter.com/bayanat_ai
LinkedIn:
https://www.linkedin.com/company/bayanatg42/
Instagram:
https://www.instagram.com/bayanat.g42/
Facebook:
https://www.facebook.com/bayanat.g42
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005443/en/
Contact information
For media enquiries, please send an email to: g42@trailrunnerint.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom